<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 10-Q


|X| Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
    Act of 1934 for the Period Ended March 31, 1999.

                                       or

| | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange
    Act of 1934 for the Transition Period From _____________ to _______________.

    Commission file number 0-27436
                           -------

                           TITAN PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)

                    DELAWARE                                94-3171940
                    --------                                ----------
         (State or Other Jurisdiction of                 (I.R.S. Employer
         Incorporation or Organization)                 Identification No.)

    400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO, CALIFORNIA 94080
    ------------------------------------------------------------------------
           (Address of Principal Executive Offices including zip code)

                                 (650) 244-4990
                                 --------------
              (Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the Registrant (1) has filed all reports 
required to be filed by Section 13 or 15(d) of the Exchange Act during the 
preceding 12 months (or for such shorter period that the registrant was 
required to file such reports), and (2) has been subject to such filing 
requirements for the past 90 days. Yes /X/ No / /

There were 15,378,053 shares of the Registrant's Common Stock issued and 
outstanding on May 7, 1999.

<PAGE>

                           TITAN PHARMACEUTICALS, INC.
                               INDEX TO FORM 10-Q
<TABLE>
<CAPTION>
PART I.     FINANCIAL INFORMATION...........................................PAGE
                                                                            ----
<S>                                                                         <C> 
            Item 1.  Condensed Financial Statements (unaudited)

            Condensed Consolidated Balance Sheets
                 March 31, 1999 and December 31, 1998..........................2

            Condensed Consolidated Statements of Operations
                 Three months ended March 31, 1999 and 1998 and period
                 from commencement of operations (July 25, 1991) 
                 to March 31, 1999.............................................3

            Condensed Consolidated Statements of Cash Flows 
                 Three months ended March 31, 1999 and 1998 and period
                 from commencement of operations (July 25, 1991) 
                 to March 31, 1999.............................................4

            Notes to Condensed Consolidated Financial
                 Statements - March 31, 1999...................................6

            Item 2.  Management's Discussion and Analysis
                 and Results of Operations.....................................7

            Item 3.  Quantitative and Qualitative Disclosures
                 About Market Risk.............................................9

PART II.    OTHER INFORMATION

            Item 6.  Exhibits and Reports on Form 8-K.........................10

SIGNATURES....................................................................11
</TABLE>
<PAGE>

                           TITAN PHARMACEUTICALS, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                     CONDENSED CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
                                                                                  March 31,              December 31,
                                                                                    1999                     1998
                                                                                 (unaudited)               (Note A)
                                                                                --------------          --------------
<S>                                                                             <C>                     <C>
Assets
Current assets
      Cash and cash equivalents                                                  $ 14,791,511            $ 11,654,896
      Prepaid expenses and other current assets                                       185,795                 139,958
                                                                                --------------          --------------
          Total current assets                                                     14,977,306              11,794,854
Furniture and equipment, net                                                          454,720                 416,956
Other assets                                                                           15,783                  15,783
                                                                                --------------          --------------
                                                                                 $ 15,447,809            $ 12,227,593
                                                                                --------------          --------------
                                                                                --------------          --------------
Liabilities and Stockholders' Equity
Current Liabilities
      Accounts payable                                                           $    864,285                 410,235
      Accrued legal fees                                                               36,900                 108,393
      Accrued clinical trials expense                                                 270,758                 653,218
      Accrued payroll and related                                                     200,986                 182,647
      Accrued professional and accounting fees                                         96,268                 125,730
      Other accrued liabilities                                                       175,000                 100,000
                                                                                --------------          --------------
          Total current liabilities                                                 1,644,197               1,580,223
Commitments
Minority interest - Series B preferred stock of Ingenex, Inc.                       1,241,032               1,241,032
Stockholders' Equity
      Preferred stock, at amounts paid in                                           5,000,000               5,000,000
      Common stock, at amounts paid in                                             58,224,313              52,291,369
      Additional paid-in capital                                                    6,524,247               6,524,204
      Deferred compensation                                                          (243,640)               (286,580)
      Deficit accumulated during the development stage                            (56,942,340)            (54,122,655)
                                                                                --------------          --------------
          Total stockholders' equity                                               12,562,580               9,406,338
                                                                                --------------          --------------
                                                                                 $ 15,447,809            $ 12,227,593
                                                                                --------------          --------------
                                                                                --------------          --------------
</TABLE>
          Note A: The balance sheet at December 31, 1998 has been derived from
          the audited financial statements at that date but does not include all
          of the information and footnotes required by generally accepted
          accounting principles for complete financial statements.

               See Notes to Condensed Consolidated Financial Statements

                                       2

<PAGE>

                           TITAN PHARMACEUTICALS, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                  (UNAUDITED)

<TABLE>
<CAPTION>
                                                                                                             COMMENCEMENT
                                                                                                             OF OPERATIONS
                                                                   THREE MONTHS ENDED MARCH 31,           (JULY 25, 1991) TO
                                                                    1999                  1998              MARCH 31, 1999
                                                               --------------       --------------          ---------------
<S>                                                            <C>                  <C>                   <C>
License and grant revenue                                       $     46,660         $          -            $  17,944,941

Costs and expenses:
      Research and development                                     2,084,973            1,686,240               46,788,652
      Acquired in-process research and development                   135,785                    -               10,321,785
      General and administrative                                     787,454            1,029,620               22,837,277
                                                               --------------       --------------          ---------------
          Total costs and expenses                                 3,008,212            2,715,860               79,947,714
                                                               --------------       --------------          ---------------
          Loss from operations                                    (2,961,552)          (2,715,860)             (62,002,773)
Other income (expense):
      Equity in loss of Ansan Pharmaceuticals, Inc.                        -                    -               (2,046,939)
      Gain on sale of technology                                           -                    -                8,361,220
      Interest income                                                151,462              263,819                2,836,204
      Interest expense                                                     -                  (87)              (4,389,902)
      Other income (expense)                                          (9,595)              55,626                  254,936
                                                               --------------       --------------          ---------------
          Other income (expense) - net                               141,867              319,358                5,015,519
                                                               --------------       --------------          ---------------
Loss before minority interest                                     (2,819,685)          (2,396,502)             (56,987,254)
Minority interest in losses of subsidiaries                                -                    -                   44,914
                                                               --------------       --------------          ---------------
Net loss                                                        $ (2,819,685)        $ (2,396,502)           $ (56,942,340)

Deemed dividend upon conversion of preferred stock                         -                    -               (5,431,871)
                                                               --------------       --------------          ---------------

Net loss attributable to common stockholders                    $ (2,819,685)        $ (2,396,502)           $ (62,374,211)
                                                               --------------       --------------          ---------------
                                                               --------------       --------------          ---------------
Basic and diluted net loss per common share                     $      (0.19)        $      (0.18)
                                                               --------------       --------------
                                                               --------------       --------------
Shares used in computing basic and diluted net loss per share     14,686,694           13,078,801
                                                               --------------       --------------
                                                               --------------       --------------
</TABLE>
               See Notes to Condensed Consolidated Financial Statements

                                       3
<PAGE>

                           TITAN PHARMACEUTICALS, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                  (UNAUDITED)
<TABLE>
<CAPTION>
                                                                                                               PERIOD FROM
                                                                                                              COMMENCEMENT
                                                                      THREE MONTHS ENDED MARCH 31,            OF OPERATIONS
                                                                   -----------------------------------     (JULY 25, 1991) TO
                                                                        1999                1998              MARCH 31, 1999
                                                                   --------------       --------------        --------------
<S>                                                                <C>                  <C>                <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss                                                            $ (2,819,685)       $ (2,396,502)         $ (56,942,340)
Adjustments to reconcile net loss to net cash used
  in operating activities:
   Depreciation and amortization expense                                  88,399              70,580              1,830,703
   Issuance of common stock to acquire technology                              -                   -              5,500,000
   Payment of guaranteed security value                                        -          (3,044,409)            (3,044,409)
   Loss on sale of assets                                                      -                   -               (203,683)
   Accretion of discount on indebebtedness                                     -                   -              2,290,910
   Equity in loss of Ansan Pharmaceuticals, Inc.                               -                   -              2,046,940
   Other                                                                       -                   -                (35,653)
   Issuance of common stock to acquire
            minority interest of Theracell, Inc.                         135,785                   -                821,785
   Changes in operating assets and liabilities:
     Prepaid expenses and other current assets                           (45,837)            (62,963)              (185,795)
     Receivable from Ansan Pharmaceuticals, Inc.
     Other receivables                                                         -             371,793                      -
     Other assets                                                              -              (1,000)               (20,748)
     Accounts payable                                                    454,050              44,048              1,188,475
     Other accrued liabilities                                          (390,076)           (338,604)             1,180,328
                                                                   --------------       --------------         -------------
Net cash used in operating activities                                 (2,577,364)         (5,357,057)           (45,573,487)
                                                                   --------------       --------------         -------------
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of furniture and equipment                                      (83,223)            (43,897)            (1,557,336)
Proceeds from sale of furniture and equipment                                  -                   -                 24,791
Purchase of short-term  investments                                            -                   -            (59,782,493)
Proceeds from sale of short-term investments                                   -                   -             59,782,493
Effect of deconsolidation of
    Ansan Pharmaceuticals, Inc.                                                -                   -               (135,934)
                                                                   --------------       --------------         -------------
Net cash (used in)/provided by investing activities                      (83,223)            (43,897)            (1,668,479)
                                                                   --------------       --------------         -------------
                                                                   --------------       --------------         -------------
</TABLE>
               See Notes to Condensed Consolidated Financial Statements

                                       4
<PAGE>

                           TITAN PHARMACEUTICALS, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                  (UNAUDITED)
<TABLE>
<CAPTION>
                                                                                                               PERIOD FROM
                                                                                                              COMMENCEMENT
                                                                                                              OF OPERATIONS
                                                                      THREE MONTHS ENDED MARCH 31,         (JULY 25, 1991) TO
                                                                        1999                1998              MARCH 31, 1999
                                                                   --------------       --------------        --------------
<S>                                                                <C>                  <C>                    <C>
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock                                               5,797,159             144,522             36,038,915
Deferred financing costs                                                     -                   -                 (713,899)
Issuance of preferred stock                                                  -                   -               22,601,443
Proceeds from notes and advances payable                                     -                   -                2,681,500
Repayment of notes payable                                                   -                   -               (1,441,500)
Proceeds from Ansan bridge financing                                         -                   -                1,425,000
Proceeds from Titan Pharmaceuticals, Inc. and
    Ingenex, Inc. bridge financing                                           -                   -                5,250,000
Repayment of Titan Pharmaceuticals, Inc. and
    Ingenex, Inc. bridge financing                                           -                   -               (5,250,000)
Proceeds from capital lease bridge financing                                 -                   -                  658,206
Payments of principle under capital lease obligation                         -                   -                 (633,766)
Proceeds from Ingenex, Inc. technology financing                             -                   -                2,000,000
Principal payments on Ingenex, Inc. technology financing                     -                   -               (2,000,000)
Increase (decrease) in minority interest                                     -                   -                1,241,032
Issuance of common stock by subsidiaries                                      43                 -                  176,546
                                                                   --------------      --------------         --------------
Net cash provided by/(used in) financing activities                    5,797,202             144,522             62,033,477
                                                                   --------------      --------------         --------------
Net (decrease)/increase in cash and cash equivalents                   3,136,615          (5,256,432)            14,791,511
Cash and cash equivalents, beginning of period                        11,654,896          24,386,872                      -
                                                                   --------------      --------------         --------------
Cash and cash equivalents, end of period                            $ 14,791,511        $ 19,130,440           $ 14,791,511
                                                                   --------------      --------------         --------------
                                                                   --------------      --------------         --------------
Supplemental cash flow disclosure
Interest paid                                                       $        -          $         87           $  1,393,524
                                                                   --------------      --------------         --------------
                                                                   --------------      --------------         --------------
Conversion of notes payable to related parties and
    accrued interest into Series A preferred stock                  $        -          $        -             $ (1,306,329)
                                                                   --------------      --------------         --------------
                                                                   --------------      --------------         --------------
Acquisition of furniture and equipment pursuant to
    capital lease                                                   $        -          $        -             $    595,236
                                                                   --------------      --------------         --------------
                                                                   --------------      --------------         --------------
Cashless exercise of warrants                                       $        -          $        -             $    871,892
                                                                   --------------      --------------         --------------
                                                                   --------------      --------------         --------------
</TABLE>
               See Notes to Condensed Consolidated Financial Statements

                                       5
<PAGE>

1.   ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

THE COMPANY AND ITS SEVERAL DEVELOPMENT STAGE SUBSIDIARIES

     Titan Pharmaceuticals, Inc. (the "Company" or "Titan"), was incorporated 
in February 1992 in the State of Delaware. Titan is a biopharmaceutical 
company developing proprietary therapeutics for the treatment of central 
nervous system disorders, cancer and other serious and life-threatening 
diseases. Titan conducts a portion of its operations through two 
subsidiaries: Ingenex, Inc. ("Ingenex") and ProNeura, Inc. ("ProNeura"), 
collectively, (the "Operating Companies"). In March 1999, a third Company 
subsidiary, Theracell, Inc. ("Theracell"), was merged with and into Titan.

    INGENEX, INC.

     Ingenex is engaged in the development of gene-based therapeutics for the 
treatment of cancer. In September 1994, Ingenex issued shares of its Series B 
convertible preferred stock to a third party for $1,241,032, net of issuance 
costs. In June 1997, Ingenex sold a research technology and certain fixed 
assets for $8,722,500 in cash and the assumption of certain capital lease 
liabilities and recognized a gain of $8,361,220. At March 31, 1999, the 
Company owned 81% of Ingenex, assuming the conversion of all preferred stock 
to common.

    PRONEURA, INC.

     ProNeura was incorporated in October 1995 to engage in the development 
of cost effective, long term treatment solutions to neurologic and 
psychiatric disorders through an implantable drug delivery system. At March 
31, 1999, the Company owned 79% of ProNeura.

    THERACELL MERGER

     On March 10, 1999, Theracell was merged with and into Titan. Pursuant to 
the merger, the Company recorded an in-process research and development 
expense of approximately $136,000, related to the acquisition of the shares 
held by the minority shareholders.

BASIS OF PRESENTATION

     The accompanying unaudited condensed consolidated financial statements 
include the accounts of Titan and its majority owned subsidiaries after 
elimination of all significant intercompany accounts and transactions. These 
financial statements have been prepared in accordance with generally accepted 
accounting principles for interim financial information and with the 
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they 
do not include all of the information and footnotes required by generally 
accepted accounting principles for complete financial statements. In the 
opinion of management, all adjustments (consisting of normal recurring 
accruals) considered necessary for a fair presentation have been included. 
Operating results for the three-month period ended March 31, 1999 are not 
necessarily indicative of the results that may be expected for the year ended 
December 31, 1999. These financials should be read in conjunction with the 
audited consolidated financial statements and footnotes thereto included in 
the Titan Pharmaceuticals, Inc. annual report on Form 10-K for the year ended 
December 31, 1998.

2. SEGMENT INFORMATION

      The Company and its Operating Companies operate in one industry 
segment, principally the development of proprietary therapeutics for the 
treatment of central nervous system disorders, cancer and other serious and 
life-threatening diseases.

3. COMPREHENSIVE INCOME

      During the three months ended March 31, 1999 and 1998, the Company's 
comprehensive loss was the same as the Company's net loss for such periods.

4. NET LOSS PER SHARE

      Had the Company been in a net income position, diluted earnings per 
share for the three months ended March 31, 1999 and 1998 would have included 
the shares used in the computation of basic net loss per share and the 
dilutive effect of 11,772,473 and 11,490,631 shares, respectively, related to 
outstanding options and warrants (prior to the application of the treasury 
stock method.)

5. NEW ACCOUNTING STANDARDS

      In June 1998, the FASB issued Statement No. 133, "Accounting for 
Derivative Instruments and Hedging Activities" ("SFAS 133"), which is 
required to be adopted in years beginning after June 15, 1999. Because the 
Company does not use derivatives, the adoption of SFAS 133 will not effect 
the Company's consolidated results of operations and financial position.

                                       6

<PAGE>

ITEM 2.    MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

     The following discussion contains certain forward-looking statements, 
within the meaning of the "safe harbor" provisions of the Private Securities 
Litigation Reform Act of 1995, the attainment of which involves various risks 
and uncertainties. Forward-looking statements may be identified by the use of 
forward-looking terminology such as "may," "will," "expect," "believe," 
"estimate," "anticipate," "continue" or similar terms, variations of those 
terms or the negative of those terms. The Company's actual results may differ 
materially from those described in these forward-looking statements due to, 
among other factors, the results of ongoing research and development 
activities and preclinical testing, the results of clinical trials and the 
availability of additional financing through corporate partnering 
arrangements or otherwise.

RESULTS OF OPERATIONS

     Since its inception, the Company's efforts have been principally devoted 
to acquiring technologies, raising capital, research, clinical development, 
and securing patent protection. At March 31, 1999, the Company had an 
accumulated deficit of approximately $56,942,000, resulting from expenditures 
for research and development and general and administrative activities.

     There was approximately $47,000 in revenues from a U.S. government grant 
for the three months ended March 31, 1999 compared to no revenues for the 
three months ended March 31, 1998.

     Research and development expenses for the 1999 quarter were 
approximately $2,085,000 compared with $1,686,000 for the 1998 quarter, an 
increase of 24%. The increase is due to the initiation and furtherance of the 
Company's cancer clinical trials. During the 1999 quarter Theracell, Inc., 
a subsidiary of the Company, was merged with and into Titan. As a result, the 
Company recorded an in-process research and development expense of 
approximately $136,000.

     General and administrative expenses for the 1999 quarter were 
approximately $787,000 compared with $1,030,000 for the 1998 quarter, a 
decrease of 24%. The decrease can be attributed to planned reductions in 
personnel expenses and other administrative costs.

     Other income and expenses, net for the 1999 quarter was approximately 
$142,000 compared to approximately $319,000 for the 1998 quarter, a net 
change of approximately $177,000. Other income for the 1999 quarter includes 
interest income of approximately $151,000 compared to $264,000 during the 
1998 quarter.

IMPACT OF YEAR 2000

         GENERAL

         The "Year 2000 Issue" is the result of computer programs being 
written using two digits rather than four to define the applicable year. 
Computer programs or hardware that have date-sensitive software or embedded 
chips may recognize a date using "00" as the year 1900 rather than the year 
2000. This could result in a system failure or miscalculations causing 
disruptions of operations, including, among other things, a temporary 
inability to process transactions, or engage in similar normal business 
activities.

         SYSTEM ASSESSMENT

         Titan is a relatively young company, incorporated in 1992, and most 
of its Information Technology ("IT") and Non-IT systems were Year 2000 
compliant when purchased. The Company believes, therefore, it will not be 
required to implement significant modifications or replace significant 
portions of its software and hardware in order to be Year 2000 compliant. The 
Company is, however, taking steps to ensure that the Year 2000 Issue does not 
have a material impact on the operation of the Company.

         Significant functions related to the Company's clinical trials are 
carried out by contract research organizations ("CRO's"). These functions 
include, but are not limited to, clinical study monitoring, 

                                       7

<PAGE>

biostatistics, data management and drug manufacturing. To the extent that the 
systems of CRO's produce incorrect information or cause incorrect 
interpretation of the information that they produce, the Company is at risk 
for making invalid conclusions about the nature, efficacy, or safety of its 
products or technologies which could lead to abandoning potentially lucrative 
products or technologies or invalidly continuing development and pursuing FDA 
approval of others. The Company is in the process of contacting its 
significant suppliers and CRO's and requesting that they provide certificates 
of compliance with relation to this issue. At this time the Company is not 
aware of any suppliers or CRO's with a Year 2000 Issue that would materially 
impact the Company's results of operations, liquidity, or capital resources. 
However, the Company has no means of ensuring that its suppliers or CRO's 
will be Year 2000 ready. The inability of its suppliers or CRO's to complete 
their Year 2000 resolution process in a timely fashion could materially 
impact the Company. The effect of non-compliance by other external agents is 
not determinable.

         COSTS AND CONTINGENCIES

          To date, the Company has expended only internal costs to assess the 
Year 2000 Issue. Letters of Year 2000 compliance from internal software 
providers tend to indicate that the Company will not be exposed to any 
material expenditures for replacements of such systems, however there can be 
no assurance of this. Also, it is not yet possible to ascertain if any 
expenditure will be required to replace systems, subcontractors or the work 
performed by such subcontractors. While vendor assurances and internal 
testing are useful in assessing Year 2000 issues, neither can provide 
absolute assurance that no Year 2000 problems will or can occur. During 1999, 
the Company will continue to refine its plans in an attempt to assure the 
Year 2000 Issue will not materially adversely affect their business 
operations or financial condition.

LIQUIDITY AND SOURCES OF CAPITAL

         The Company has funded its operation from inception primarily 
through private and public sales of its securities and corporate 
partnerships. During 1997, the Company received approximately $25,861,000 
from license fees and the sale of a research technology.

         In January 1999, the Company completed a private placement of 
2,254,545 shares of its Common Stock for net proceeds of approximately 
$5,798,000, after deducting fees and commissions and other expenses of the 
offering.

         In November 1998, the Company agreed to guarantee certain potential 
obligations of the Company's Chief Executive Officer, related to the 
Company. The Company's Chief Executive Officer has pledged approximately 
300,000 shares of the Company's common stock, owned by the Chief Executive 
Officer, to secure the guarantee by the Company.  Under said guarantee, the 
Company may be obligated to make a payment of up to $400,000.

         Titan has entered into various agreements with contract research 
organizations, academic institutions, and other entities for the performance 
of research and development activities and for the maintenance of licenses 
related to those activities. The aggregate commitments the Company has under 
these agreements, including minimum license payments, for the next 12 months 
is approximately $2,412,000. Certain of the licenses provide for the payment 
of royalties by the Company on future product sales, if any. In addition, in 
order to maintain license and other rights while products are under 
development, the Company must comply with customary licensee obligations, 
including the payment of patent related costs and meeting project-funding 
milestones.

         The Company expects to continue to incur substantial additional
operating losses from costs related to continuation and expansion of research
and development, clinical trials, and increased administrative and fund raising
activities over at least the next several years. To preserve operating capital,
the Company has chosen to strategically focus on development of its later stage
products in clinical development, and at least temporarily reduce or eliminate
spending on certain preclinical programs. While the Company has sufficient
working capital to sustain planned operations for a period greater than 12
months, the Company may seek 

                                       8

<PAGE>

additional financing, depending on numerous factors including, but not 
limited to, the progress of the Company's research and development programs, 
the results of clinical studies, technological advances, determinations as to 
the commercial potential of the Company's products, and the status of 
competitive products. In May 1998, the Company negotiated a $5,000,000 bank 
line of credit. To date the Company has not borrowed against this facility. 
In addition, certain expenditures will be dependent on the establishment of 
collaborative relationships with other companies, the availability of 
financing, and other factors. In any event, the Company anticipates that it 
will require substantial additional financing in the future. There can be no 
assurance as to the availability or terms of any required additional 
financing, when and if needed.


ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

     The Company has reviewed the requirements of Item 3 and has determined 
that these disclosures are not applicable.


                                       9

<PAGE>

                                     PART II


ITEM 6.    EXHIBITS AND REPORTS ON FORM 8-K

<TABLE>
<CAPTION>
           (a)   Exhibits
                 27.1        Financial Data Schedule
<S>              <C>
           (b)   Reports on Form 8-K
                 A current report on Form 8-K was filed with the Securities and
                 Exchange Commission on January 28, 1999.
</TABLE>

                                       10
<PAGE>

                                   SIGNATURES


     In accordance with the requirements of the Exchange Act, the registrant 
caused this report to be signed on its behalf by the undersigned, thereunto 
duly authorized.


                                 TITAN PHARMACEUTICALS, INC.

         May 17, 1999            By: /s/Louis R. Bucalo
                                     ------------------
                                     Louis R. Bucalo,  M.D., President and
                                     Chief Executive Officer

         May 17, 1999            By: /s/Robert E. Farrell
                                     --------------------
                                     Robert E. Farrell, Chief Financial Officer



                                      11